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ORIGINAL ARTICLE
Histamine Receptor 2 is Required to Suppress Innate Immune
Responses to Bacterial Ligands in Patients with Inﬂammatory
Bowel Disease
Sylwia Smolinska, PhD,*,† David Groeger, PhD,‡,§ Noelia Rodriguez Perez, PhD,‡ Elisa Schiavi, PhD,‡
Ruth Ferstl, PhD,‡ Remo Frei, PhD,‡,¶ Patrycja Konieczna, PhD,‡ Cezmi A. Akdis, MD,‡
Marek Jutel, MD, PhD,*,† and Liam O’Mahony, PhD‡
Background: Histamine is a key immunoregulatory mediator in immediate-type hypersensitivity reactions and chronic inﬂammatory responses, in
particular histamine suppresses proinﬂammatory responses to bacterial ligands, through histamine receptor 2 (H2R). The aim of this study was to
investigate the effects of histamine and H2R on bacteria-induced inﬂammatory responses in patients with IBD.
Methods: Peripheral blood mononuclear cells (PBMCs) were obtained from patients with Crohn’s disease, patients with ulcerative colitis, and healthy
controls. PBMC histamine receptor expression was evaluated by ﬂow cytometry. Cytokine secretion following Toll-like receptor (TLR)-2, TLR-4,
TLR-5, or TLR-9 stimulation in the presence or absence of histamine or famotidine (H2R antagonist) was quantiﬁed. Biopsy histamine receptor gene
expression was evaluated using reverse transcription–polymerase chain reaction. The in vivo role of H2R was evaluated in the T-cell transfer murine
colitis model.
Results: The percentage of circulating H2R+ monocytes was signiﬁcantly reduced in patients with IBD. Histamine effectively suppressed TLR-induced
cytokine secretion from healthy volunteer PBMCs but not for PBMCs from patients with IBD. Famotidine reversed this suppressive effect. H1R, H2R,
and H4R gene expression was increased in inﬂamed gastrointestinal mucosa compared with noninﬂamed mucosa from the same patient and expression
levels correlated with proinﬂammatory cytokine gene expression. Mice receiving lymphocytes from H2R2/2 donors, or treated with famotidine,
displayed more severe weight loss, higher disease scores and increased numbers of mucosal IFN-g+ and IL-17+ T cells.
Conclusion: Patients with IBD display dysregulated expression of histamine receptors, with diminished anti-inﬂammatory effects associated with H2R
signaling. Deliberate manipulation of H2R signaling may suppress excessive TLR responses to bacteria within the gut.
(Inﬂamm Bowel Dis 2016;22:1575–1586)
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C rohn’s disease and ulcerative colitis are the 2 major forms ofinﬂammatory bowel disease (IBD), and both diseases are
chronic immune-mediated disorders of the gastrointestinal tract,
associated with signiﬁcant morbidity and health care costs. The
precise mechanisms driving these diseases remain unknown but
complex interactions between the immune system, enteric micro-
biota, and host genotype underlie the development of IBD.1 Com-
ponents of the intestinal microbiota can drive protective or
pathological responses in IBD models, highlighting the impor-
tance of host–microbe communication in the development of
these diseases.2,3 The innate immune system responds to micro-
bial components or products through activation of pattern recog-
nition receptors, including Toll-like receptors (TLRs), which are
transmembrane pattern recognition receptors located either on the
cell surface or in the endosomes.4 Several regulatory mechanisms
that control TLR activation have been described, thus preventing
excessive inﬂammatory responses to the resident microbiota.5 In
particular, many host-derived and environment metabolites can
inﬂuence immune reactivity and TLR activation, with signiﬁcant
effects on mucosal immune homeostasis.6 Coordination between
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multiple pattern recognition receptor signaling pathways is impor-
tant for the induction of the appropriate innate and adaptive
response. For example, TLR-2 recognition of a Biﬁdobacterium
strain promotes dendritic cell interleukin (IL)-10 and retinoic acid
secretion, whereas tumor necrosis factor alpha (TNF-a) and IL-12
secretion is suppressed.7
Histamine is a biogenic amine, which induces a range of
immunoregulatory activities in innate and adaptive immune cells.8
Four histamine receptors have been described (H1R–H4R), and
histamine-induced immune effects are dependent on the type of
receptor expressed by a speciﬁc cell.9 H2R has been shown to
exert regulatory effects in multiple models. Dendritic cell proin-
ﬂammatory responses to microbial ligands are signiﬁcantly sup-
pressed by means of histamine binding to the H2R, whereas
suppression of IL-27 secretion was mediated by means of both
H2R and H4R.
10,11 Murine H2R knock out mice display defects in
gastric and immune regulatory functions, whereas mucosal
expression of H2R is critical for immunomodulatory responses
to bacteria-derived histamine.12,13 T-cell expression of H2R has
dramatic effects on lymphocyte polarization, whereas H2R
expression by allergen-speciﬁc TH2 cells directly suppresses
allergen-stimulated T cells but promotes IL-10 production.14,15
Interestingly, mucosal histamine levels, but not plasma levels,
were shown to be increased in patients with IBD, and increased
urinary levels of N-methylhistamine, a stable histamine metabo-
lite, correlated with disease activity in both patients with Crohn’s
disease and patients with ulcerative colitis.16–18 However, expres-
sion of the different histamine receptors and the functional effects
of histamine signaling on TLR responses to microbial ligands
have not been previously described for patients with IBD. We
describe that histamine does not suppress proinﬂammatory cyto-
kine responses to TLR ligands as effectively for peripheral blood
mononuclear cells (PBMCs) from patients with IBD when com-
pared with healthy controls, which correlates with reduced H2R
expression by peripheral blood monocytes. Histamine receptor
expression is increased in inﬂamed mucosa, whereas blocking
H2R in a murine T-cell transfer colitis model exacerbates disease.
MATERIALS AND METHODS
Human Studies
In this study, 22 healthy volunteers, 21 patients with Crohn’s
disease and 21 ulcerative colitis patients were recruited from the
Department of Clinical Gastroenterology of IV Military Hospital
and First Department and Clinic of General, Gastroenterological
and Endocrinological Surgery in Wroclaw, Poland. Patient demo-
graphic details are included in Table 1. All patients and healthy
volunteers read and signed an informed consent form before
recruitment. The study-speciﬁc procedures were approved by the
Wroclaw Medical University Ethics Committee. The diagnosis of
Crohn’s disease or ulcerative colitis was based on clinical, radio-
logical, and endoscopic examination and histological ﬁndings.
Patients were excluded if immunosuppressive medications were
taken within 1 month of blood sampling. All recruited patients were
in the active stage of disease. Following recruitment, 50 mL of
peripheral blood was obtained from each volunteer. Biopsy-
derived complementary DNA from 10 patients with Crohn’s dis-
ease and 10 ulcerative colitis patients were provided by the Swiss
IBD Cohort Biobank (http://ibdcohort.ch). Written informed con-
sent was obtained before specimen collection, and studies were
approved by the regional Swiss Ethics Committees in which cohort
participants were enrolled.
PBMCs Isolation and Cryopreservation
Mononuclear cells were isolated from 50 mL of peripheral
blood using the Boyüm method. After resuspending blood in
phosphate-buffered solution, without calcium and magnesium, cells
were separated by density gradient centrifugation on ﬁcoll. The mono-
nuclear cell layer was collected and washed 2 times in phosphate-
buffered solution. Cells were counted using a Neubauer chamber and
then resuspended in freezing medium (45% fetal calf serum [FCS],
45% Roswell Park Memorial Institute medium [RPMI], 10%
dimethyl sulfoxide [DMSO]) at a concentration of 1 · 106 cells per
milliliter. Cells were stored in liquid nitrogen until further analysis.
In Vitro Cell Culture
Following careful resuscitation and acclimatization of the
PBMCs at 378C, cells were cultured in cRPMI media (Gibco; Thermo
Fisher Scientiﬁc, Waltham, MA) at a concentration of 1 · 106 cells
per milliliter. Cells were stimulated with the TLR ligands Pam3Cys
(0.5 mg/mL; Calbiochem, Darmstadt, Germany), lipopolysaccharide
(LPS) (500 ng/mL; Sigma-Aldrich, Buchs, Switzerland), ﬂagellin
(100 ng/mL; Invivogen, San Diego, CA), or CpG (100 mM; Micro-
synth, Balgach, Switzerland) or remained unstimulated for 24 hours.
In total, 1 · 1025M histamine (Sigma-Aldrich) was added 10 minutes
before TLR ligands, whereas the H2R antagonist famotidine (Sigma-
Aldrich) was added 30 minutes before histamine at a concentration of
1 · 1025M. Supernatants were collected after 24 hours, and cytokines
TABLE 1. Patient Demographics
Healthy
Controls
Crohn’s
Disease
Ulcerative
Colitis P
n 22 21 21
Age (SD) 37.9 (13.0) 38.7 (11.5) 43.0 (15.2) 0.241
Male/female 9/13 11/10 13/8 0.386
Disease duration, yr 4.9 4.4 0.697
Current therapy
5-Aminosalicylates 13 16 0.317
Biologics 1 0 0.315
Nutritional therapya 9 2 0.014
PPI 4 1 0.153
Antibiotics 7 1 0.018
aNutritional therapy includes multivitamins, iron, and/or vitamin B supplementation.
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were quantiﬁed using the Bioplex Multiplex Suspension Array Sys-
tem (Bio-Rad Laboratories, Hercules, CA).
Flow Cytometry Analysis
All ﬂow cytometry analyses were performed on the Gallios
Flow Cytometer (Beckman Coulter, Brea, CA). Antibodies to
CXCR3, T-bet, IFN-g (TH1 panel), CCR4, CRTh2, GATA-3, IL-5,
IL-13 (TH2 panel), CD161, CCR6, ROR-gt, IL-17 (TH17 panel),
CD3, CD4, CD14, and CD19 were obtained from eBioscience
(Vienna, Austria). Labeled anti-human H1R antibody was obtained
from R&D Systems (Minneapolis, MN). Anti-human H2R (GeneTex;
Lucerna-Chem, Luzern, Switzerland) and anti-human H4R (Alomone
Labs, Jerusalem, Israel) were labeled using DyLight Fluorescent
Dyes (Thermo Scientiﬁc, Schwerte, Germany). Staining with anti-
histamine receptor antibodies was validated in cell lines and primary
cells with known levels of histamine receptor gene expression. Each
batch of antibodies was validated before use because signiﬁcant
batch-to-batch variations were noted. Only one validated batch of
antibody was used for the entire study. Flow cytometry results were
analyzed in Kaluza Flow Analysis Software (Beckman Coulter).
Gene Expression
PBMC messenger RNA was isolated using RNeasy Mini
Kit and QIA-Shredder-Kit (Qiagen, Venlo, the Netherlands).
Reverse transcription was performed using RevertAid RT Kit
(Thermo Fisher Scientiﬁc). Real-time polymerase chain reaction
was performed with iTaq SYBR Green Supermix with ROX (Bio-
Rad Laboratories). The primers used are listed in Supplementary
Table S1, Supplemental Digital Content 1, http://links.lww.com/
IBD/B274, and all were synthesized by Microsynth.
Severe Combined Immunodeﬁcient T-cell
Transfer Colitis Model
The C.B-17 severe combined immunodeﬁcient (SCID) mice
were obtained from Charles River (Sulzfeld, Germany) and
maintained under speciﬁc pathogen-free conditions. The animals
were housed at the AO Research Institute (Davos, Switzerland) in
individually ventilated cages for the duration of the study, and all
experimental procedures were carried out in accordance with Swiss
law. Colitogenic CD4+CD252CD45RBhigh cells were isolated from
BALB/c wild-type or BALB/c H2R2/2 donor mouse spleens using
the MACS system (depletion of CD4+CD25+ cells followed by
positive selection of CD45RB FITC-labeled cells). Colitis was
induced by intraperitoneal transfer of 4 · 105 cells per C.B-17
SCID mouse at day 0. Half of the animals, which received wild-
type T cells, were daily injected intraperitoneally with famotidine
(20 mmol/kg), whereas the remaining animals received daily NaCl
injections intraperitoneally. Disease severity scores were recorded,
whereas animal weights were monitored every day. Disease sever-
ity scores included feces condition (1 ¼ wet; 2 ¼ diarrhea; 3 ¼
bloody diarrhea or rectal prolapse), activity (1 ¼ isolated, abnormal
position; 2 ¼ huddled, hypoactive, or hyperactive; 3 ¼ uncon-
scious), coordination of movement (1 ¼ slightly uncoordinated;
2¼ very uncoordinated; 3¼ paralysis), and fur quality (1¼ reduced
grooming; 2 ¼ disheveled; 3 ¼ hair loss). Following euthanasia
on day 22, mesenteric lymph nodes were isolated and single-cell
suspensions generated using mechanical means. IFN-g+ and IL-17+
lymphocytes were quantiﬁed by ﬂow cytometry.
Statistical Analysis
Statistical signiﬁcance between experimental conditions
was calculated using the nonparametric t test Mann–Whitney,
whereas correlations were assessed using the Pearson test. When
more than 2 groups were compared, a 1-way analysis of variance
and Dunnett post-hoc test were used to determine statistical sig-
niﬁcance. Paired t tests were used to assess the differences
between gene expression in inﬂamed versus noninﬂamed mucosa.
All data analysis was carried out using GraphPrism software
(GraphPad Sofware Inc., La Jolla, CA).
RESULTS
Monocyte H2R Expression is Downregulated
in Patients with IBD
Histamine receptor expression was evaluated on peripheral
blood mononuclear cells (PBMCs) using ﬂow cytometry. H1R
expression by peripheral blood CD14+ monocytes was not differ-
ent between the groups. However, there was a decrease in H2R+
monocytes, associated with an increase in H4R+ monocytes, in the
peripheral blood of patients with Crohn’s disease and ulcerative
colitis (Fig. 1A). Few CD3+ T cells expressed H1R or H2R, with
greater numbers expressing H4R. No differences in T-cell hista-
mine receptor expression were observed between the groups (Fig.
1B). The histamine receptor most frequently expressed by CD19+
B cells was H2R; however, there was no difference in expression
between the groups. Very few B cells express H1R or H4R, but
signiﬁcantly more H4R+ B cells were observed in the peripheral
blood of patients with ulcerative colitis (Fig. 1C). An example of
the gating strategy is illustrated in Figure 1D.
In addition, we analyzed lymphocyte polarization in periph-
eral blood by ﬂow cytometry. TH1 cells were identiﬁed as IFN-g+,
T-bet+, and CXCR3+ and TH2 cells as CRTh2+, GATA-3+, CCR4+,
IL-5+, and IL-13+, whereas TH17 cells were CD161+, ROR-gt+,
CCR6+, and IL-17+. Both patients with Crohn’s disease and ulcer-
ative colitis had elevated TH1 cells (Fig. 2A) and TH17 cells (Fig.
2B) compared with healthy controls, with the increases in patients
with Crohn’s disease reaching statistical signiﬁcance. However, no
differences in TH2 cells were observed between the groups (Fig.
2C). Interestingly, a signiﬁcant inverse association was noted
between the percentage of H2R+ monocytes and the percentage of
TH17 cells in peripheral blood (Fig. 2D). No signiﬁcant correlation
was observed between the percentage of H2R+ monocytes and the
percentage of TH1 or TH2 cells in peripheral blood (Fig. 2E, F).
Cytokine Responses to TLR Ligands is
Modulated by Histamine Through H2R
PBMCs from healthy controls, patients with Crohn’s dis-
ease, and patients with ulcerative colitis were stimulated in vitro
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FIGURE 1. Low H2R expression is accompanied by high H4R expression on monocytes from patients with IBD. PBMCs were examined by ﬂow
cytometry for the expression of H1R, H2R, and H4R. CD14+ monocytes (A), CD3+ T-cell (B), or CD19+ B-cell (C) histamine receptor expression was
quantiﬁed as a percentage of the population. A representative example of the gating strategy is illustrated (D).
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with the TLR ligands Pam3Cys (TLR-2), LPS (TLR-4), ﬂagellin
(TLR-5), or CpG oligonucleotides (TLR-9) in the presence or
absence of histamine. Histamine signiﬁcantly reduced TNF-a
secretion, stimulated by all TLR ligands; however, signiﬁcantly
greater suppression of TNF-a section was observed for TLR-2,
TLR-4, and TLR-5 stimulated PBMCs from healthy controls
compared with PBMCs from patients with Crohn’s disease or
ulcerative colitis (Fig. 3A). Similarly, IL-6 secretion was sup-
pressed to a signiﬁcantly greater extent by histamine for TLR-2
stimulated PBMCs from healthy controls compared with patients
with Crohn’s disease and for TLR-5 stimulated PBMCs from
healthy controls compared with patients with Crohn’s disease or
ulcerative colitis (Fig. 3B). Histamine also suppressed TLR-2 and
TLR-5 stimulated IFN-g secretion signiﬁcantly more in PBMCs
from healthy controls compared with both disease groups (Fig.
3C), whereas suppression of IL-12p70 secretion by histamine was
signiﬁcantly greater for TLR-2 or TLR-9 stimulated healthy con-
trol PBMCs (Fig. 3D). Histamine suppression of MCP-1 secretion
FIGURE 2. TH1 and TH17 lymphocytes are increased in patients with IBD. TH1 lymphocytes (A) and TH17 lymphocytes (B) were elevated in both
patients with Crohn’s disease (CD) and patients with ulcerative colitis (UC) compared with healthy controls (HC). No change in TH2 cells (C) was
observed between the groups. The percentage of TH17 cells in peripheral blood was negatively correlated with the percentage of H2R+ monocytes
in peripheral blood (D). No correlations were observed for the percentage of H2R+ monocytes in peripheral blood and the percentage of TH1 cells
(E) or TH2 cells (F). *P , 0.05; **P , 0.01.
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by TLR-4 activation was more effective for PBMCs from healthy
controls (Fig. 3E). Finally, there was no signiﬁcant difference
between the groups for the inﬂuence of histamine on IL-17 secre-
tion (Fig. 3F). The differential effects of histamine on TLR-
induced cytokine secretion was not because of differences in
cytokine levels between the groups following TLR-stimulation
alone. Secretion of TNF-a, IL-6, IFN-g, IL-12p70, MCP-1, and
IL-17 in response to TLR-2, TLR-4, TLR-5, and TLR-9 stimula-
tion was similar for PBMCs from healthy controls, patients with
Crohn’s disease, and patients with ulcerative colitis (see Fig. S1, A–
F, Supplemental Digital Content 2, http://links.lww.com/IBD/B275).
Differences in TLR expression may be associated with altered
responses to their ligands. Therefore, we quantiﬁed TLR expression
in peripheral blood using reverse transcription–polymerase chain
reaction. There was no difference in the expression of TLR-2,
TLR-4, or TLR-5 between the groups (see Fig. 2, A–C, Supplemen-
tal Digital Content 3, http://links.lww.com/IBD/B276). However,
TLR-9 expression was signiﬁcantly reduced in the peripheral blood
of ulcerative colitis patients compared with healthy controls (see
Fig. 2D, Supplemental Digital Content 2, http://links.lww.com/
IBD/B275). Expression of the genes related to histamine synthesis
(HDC) and metabolism (HNMT and DAO) were also quantiﬁed in
FIGURE 3. Histamine suppression of TLR-induced cytokine responses is signiﬁcantly less for PBMCs from patients with IBD. Cytokine secretion from
in vitro TLR-stimulated PBMCs was suppressed by histamine. Inhibition of TNF-a (A), IL-6 (B), IFN-g (C), IL-12p70 (D), and MCP-1 (E) secretion was
signiﬁcantly greater for PBMCs co-incubated with histamine from healthy controls (HC) compared with patients with Crohn’s disease (CD) or
ulcerative colitis (UC). TLR-stimulated IL-17 secretion was not signiﬁcantly suppressed (F). Inclusion of the H2R antagonist famotidine completely
reversed histamine suppression of TLR-2 stimulated TNF-a (G) and TLR-2 stimulated IFN-g (H). Results are expressed as percentage change in
cytokine secretion from TLR-stimulated compared with TLR- and histamine-stimulated PBMCs. *P , 0.05; **P , 0.01.
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peripheral blood (Fig. 4). Although HDC and HNMT gene expres-
sion was similar for all groups, DAO gene expression was lower in
patients with Crohn’s disease and statistically signiﬁcantly lower for
patients with ulcerative colitis compared with healthy volunteers
(Fig. 4).
To determine if H2R was responsible for the histamine
effects on TLR-stimulated PBMCs, famotidine was used to block
the H2R. Famotidine reversed the inhibitory effect of histamine on
TLR-2 stimulated secretion of TNF-a (Fig. 3G) and TLR-2 stim-
ulated secretion of IFN-g (Fig. 3H).
Histamine Receptors Are Upregulated in the
Inﬂamed Mucosa
From each patient, mucosal biopsies were obtained from
inﬂamed and noninﬂamed regions, as determined by endoscopy.
Histamine receptor expression was quantiﬁed using reverse
transcription–polymerase chain reaction. Inﬂammatory activity
was conﬁrmed by quantifying IFN-g and TNF-a gene expression.
Both IFN-g and TNF-a gene expression was signiﬁcantly upregu-
lated in the biopsies from inﬂamed mucosa compared with non-
inﬂamed mucosa (Fig. 5A, B). H1R expression was upregulated in
inﬂamed mucosa from patients with ulcerative colitis but not in
inﬂamed mucosa from patients with Crohn’s disease (Fig. 5C).
H2R and H4R gene expression were increased in inﬂamed mucosa
from both patients with Crohn’s disease and patients with ulcerative
colitis (Fig. 5D, E). Within the inﬂamed mucosa of patients with
ulcerative colitis, there was a signiﬁcant positive correlation
between H4R gene expression and IFN-g gene expression, whereas
H2R gene expression correlated with TNF-a gene expression (Fig.
5F, G). No correlations between histamine receptor gene expression
and TNF-a or IFN-g gene expression were observed for patients
with Crohn’s disease. Expression of the genes related to histamine
synthesis (HDC) and metabolism (HNMT and DAO) were similar
for inﬂamed and noninﬂamed mucosa (see Fig. 3, A–F, Supple-
mental Digital Content 4, http://links.lww.com/IBD/B277).
Loss of H2R Exacerbates Colitis in
a Murine Model
Using the T-cell transfer model of colitis,19 we determined
if H2R inﬂuences disease development. SCID mice received either
TREG-depleted T cells from wild-type mice, TREG-depleted T cells
from H2R-deﬁcient mice, or TREG-depleted T cells from wild-type
mice, and in addition, these animals were treated daily with
famotidine. Weight loss began earlier and was more pronounced
in animals receiving T cells from H2R-deﬁcent mice or animals
administered famotidine (Fig. 6A). Similarly, disease severity
scores were elevated in these animals (Fig. 6B). Furthermore,
signiﬁcantly more IFN-g+ and IL-17+ lymphocytes were observed
in animals receiving T cells from H2R-deﬁcent mice or animals
administered famotidine (Fig. 6C, D). Colonic myeloperoxidase
levels were signiﬁcantly elevated in mice receiving H2R-deﬁcient
lymphocytes, with a trend for increased myeloperoxidase levels in
mice treated with famotidine (Fig. 7A). Colonic TNF-a and IL-17
gene expression was signiﬁcantly increased in both mice treated
with famotidine or H2R-deﬁcient lymphocytes, whereas IFN-g
gene expression was signiﬁcantly increased in mice receiving
H2R-deﬁcient lymphocytes with a nonstatistical signiﬁcant
increase for IFN-g gene expression in mice treated with famoti-
dine (Fig. 7B). H1R, H2R, and H4R gene expression increased in
the colon of colitic animals, with no differences in expression
being observed for mice treated with famotidine or mice receiving
H2R-deﬁcient lymphocytes compared with mice receiving wild-
type lymphocytes (Fig. 7C).
DISCUSSION
Inﬂammatory bowel diseases are chronic debilitating
inﬂammatory disorders that affect millions of people worldwide.
Even though great progress has been made in understanding the
basic inﬂammatory mechanisms that underpin mucosal inﬂam-
mation, signiﬁcant gaps have prevented the development of
meaningful new therapies. Inappropriate and exaggerated immune
responses to microbial factors within the gut are thought to play
a key role in the pathogenesis of IBD and therefore a better
understanding of the regulatory molecules, which dampen these
responses, would be highly valued. In this report, we present
evidence that histamine signaling is disrupted in both patients
with Crohn’s disease and patients with ulcerative colitis. Hista-
mine receptor expression and functional activity are altered,
which was previously unrecognized in these patients. In addition,
FIGURE 4. Decreased DAO gene expression in peripheral blood. Peripheral blood HDC and HNMT gene expression were similar for healthy
controls (HC), patients with Crohn’s disease (CD), and patients with ulcerative colitis (UC). However, DAO gene expression in peripheral blood was
decreased for patients with CD and statistically signiﬁcantly decreased for UC patients. *P , 0.05.
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FIGURE 5. Increased expression of histamine receptor genes within the inﬂamed mucosa. Expression of IFN-g (A) and TNF-a (B) was signiﬁcantly
increased in inﬂamed versus noninﬂamed biopsies from patients with Crohn’s disease (CD) and ulcerative colitis (UC). H1R (C) was elevated in inﬂamed
mucosa from UC but not from patients with CD. H2R (D) and H4R (E) were both elevated in inﬂamed mucosa from CD and UC patients. IFN-g gene
expression correlates with H4R expression (F), whereas TNF-a expression correlates with H2R (G) in inﬂamed mucosa from UC patients. *P , 0.05.
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FIGURE 6. Loss of H2R activity exacerbates disease in the T-cell transfer colitis model. Mice lost weight faster when lymphocytes were adoptively
transferred from H2R2/2 animals or when transferred with wild-type (WT) lymphocytes and treated with famotidine during the study (A). Similarly,
disease severity scores were elevated when H2R signaling was blocked (B). IFN-g+ (c) and IL-17+ (D) lymphocytes were increased in the mesenteric
lymph nodes when H2R was blocked. *P , 0.05.
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FIGURE 7. Loss of H2R activity increases colonic myeloperoxidase (MPO) levels and cytokine gene expression. Mice receiving lymphocytes from
H2R2/2 animals had signiﬁcantly elevated MPO levels compared with mice receiving wild-type (WT) lymphocytes (A). Similarly, TNF-a, IL-17, and
IFN-g gene expression were elevated when H2R signaling was blocked (B). H1R, H2R, and H4R gene expression were elevated in mice following the
induction of colitis (C). *P , 0.05.
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blocking H2R results in more severe inﬂammatory disease in the
murine T-cell transfer colitis model.
Histamine has been previously shown to signiﬁcantly
inﬂuence the intensity and polarization of immune responses,
including the recognition of microbes by TLRs.10,20–22 Using
a panel of TLR ligands, we demonstrate that histamine exerts
a diminished suppressive effect on cells from patients with IBD,
possibly due to the decreased number of H2R+ monocytes. The
decrease in H2R+ monocytes is negatively correlated with TH17
cells in peripheral blood, which parallels the animal model data
where increased IL-17+ lymphocytes were found in the mucosa of
animals treated with a H2R antagonist or animals receiving H2R-
deﬁcient lymphocytes. However, histamine did not directly sup-
press TLR-induced IL-17 secretion from PBMCs, suggesting
a direct inﬂuence of H2R on TH17 lymphocyte polarization, which
may be independent of the effect of histamine on IL-17 secretion
by innate immune cells, such as monocytes. The reasons for the
monocytes switching from H2R to H4R expression are unknown
but may include the inﬂuence of circulating proinﬂammatory cy-
tokines. H4R activation can promote TH17 responses in murine
models, and H4R signaling has been recently shown to promote
colitis in a murine model, suggesting that the balance between
H2R and H4R may be critical in controlling mucosal inﬂammatory
responses.23,24 Recently, the expression of H4R by peripheral
blood monocytes has been questioned, with high interindividual
variability of monocyte-speciﬁc H4R gene expression being re-
ported.25 However, expression of this receptor can be inﬂuenced
by pro-inﬂammatory stimuli, and increased H4R staining of
monocytes from patients with IBD may be due to ongoing inﬂam-
matory responses. Our ﬂow cytometry staining of B cells suggest
that B cells from healthy volunteers do not express the H4R (less
than 0.3% positive B cells), which agrees with previously pub-
lished B-cell data sets.26 However, a statistically signiﬁcant, but
numerically minor, increase in H4R staining was observed for B
cells from patients with ulcerative colitis. This suggests that a rel-
atively rare subpopulation of B cells may upregulate H4R in pa-
tients with ulcerative colitis. In addition to altered receptor
expression, differences in the intracellular signaling mechanisms
associated with the H2R pathway may be important. H2R modu-
lation of TLR activation is 30,50-cyclic adenosine monophosphate
dependent, with downstream effects on NF-kB activation and
cytokine secretion being mediated by exchange protein directly
activated by cyclic adenosine monophosphate (Epac).10 Epac has
also been shown to be responsible for other immune regulatory
activities such as mediating dendritic cell migration to TREG-
derived adenosine, rendering them less stimulatory.27 It is cur-
rently unknown if Epac expression or activity is modulated in
patients with IBD. Regardless of the mechanism, it is clear that
PBMCs from patients with IBD respond differently to histamine
compared with cells from healthy volunteers.
Histamine does not suppress all TLR-induced cytokines but
there clearly is speciﬁcity for speciﬁc TLR type–cytokine combi-
nations, which was previously described by us for dendritic cells.10
As TNF-a and IFN-g secretion were the most consistent cytokines
suppressed for the majority of TLRs, we evaluated gene expression
of these cytokines and histamine receptors in mucosal tissue.
Expression of proinﬂammatory cytokines, such as TNF-a and
IFN-g, was increased in the inﬂamed compared with noninﬂamed
mucosa from the same individuals. Surprisingly, expression of
TNF-a positively correlated with H2R expression, whereas IFN-g
expression positively correlated with H4R expression in ulcerative
colitis patients. Such a close association suggests that one of these
factors may inﬂuence the expression of the other or a separate
factor induces all these genes. One might expect that increased
expression of H2R would correlate with decreased, rather than
increased, TNF-a gene expression. Similarly, other regulatory fac-
tors, such as IL-10, have also been previously seen to be increased
in inﬂamed tissue, suggesting that the inﬂamed mucosal microen-
vironment drives expression of regulatory factors, which unfortu-
nately are not sufﬁcient to fully reverse the inﬂammatory response.
However, loss of IL-10 or H2R exacerbates colitis in experimental
models, which suggests that these molecules do exert some anti-
inﬂammatory effects, albeit not potent enough to reverse disease.28
Another surprising ﬁnding is that these cytokine–histamine receptor
associations were only seen in ulcerative colitis patients but not in
patients with Crohn’s disease, suggesting that the ulcerative colitis
inﬂammatory process may associate to a greater extent with dysre-
gulated histamine responses compared with the mucosal microen-
vironment of patients with Crohn’s disease. The speciﬁc cytokines
that directly inﬂuence histamine receptor expression are currently
unknown, but future studies should examine the differential inﬂu-
ence of TH1, TH2, and TH17 cytokines on histamine receptor
expression within the mucosa. One limitation of our studies on
mucosal biopsies is that gene expression analysis of the entire
biopsy does not allow us to identify which cell types are differen-
tially expressing histamine receptors within the inﬂamed mucosa.
One possibility for increased histamine receptor expression is that
certain cell types, potentially including epithelial cells, dendritic
cells, macrophages, innate lymphoid cells, invariant natural killer
T cells, T or B lymphocytes, may upregulate histamine receptor
expression. However, it is also possible that recruitment of hista-
mine receptor expressing cells to the inﬂamed tissue could alter
gene expression levels. Interestingly, H2R gene expression was
signiﬁcantly increased in the inﬂamed colon of mice that received
lymphocytes from H2R-deﬁcient donors, suggesting that cells other
than lymphocytes express the H2R in this model. Regardless, the
high level of histamine receptor expression within inﬂamed mucosa
suggests that these cells are susceptible to the immunoregulatory
inﬂuence of histamine.
Previously, other reports have described that histamine levels
are increased within the mucosa of patients with IBD, which
potentially could be due to an imbalance in histamine synthesis or
metabolism. HNMT gene expression was reported to be reduced in
inﬂamed mucosa, and DAO polymorphisms have been associated
with an increased risk of IBD.29,30 We did not observe any differ-
ences in gene expression for HDC, HNMT, or DAO in inﬂamed
compared with noninﬂamed mucosa; however, there was a decrease
in DAO gene expression within peripheral blood of patients with
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IBD, which may contribute to elevated levels of histamine previ-
ously reported in these patients. Although histamine levels are
important, the binding of histamine to different histamine receptors
is perhaps more relevant and decisive. Recently, the use of H2R
antagonists, but not proton pump inhibitors, signiﬁcantly increased
the risk of hospitalization or surgery in Crohn’s disease patients.31
In addition, we describe that transfer of T cells, which lack H2R, or
inhibition of H2R using a speciﬁc antagonist accelerates weight loss
and increases disease severity in a mouse colitis model. These
results suggest that histamine signaling through the H2R may have
protective effects within the mucosa.
In addition to IBD, inappropriate TLR signaling has been
associated with multiple inﬂammatory and infectious diseases,
particularly those of mucosal tissues.32–34 There is increasing inter-
est in the role that histamine plays in many of these pathologies.35
Taken together, it is clear that histamine and histamine receptors are
intimately connected to the ﬁne-tuning of innate immune responses
to microbes and appropriate TLR signaling. Indeed, certain mi-
crobes can secrete histamine within the gut and may directly inﬂu-
ence gastrointestinal inﬂammation through H2R.
13,36 The deliberate
activation of H2R, or its associated signaling pathways, is a novel
therapeutic target for inﬂammatory diseases. However, the micro-
environmental or genetic polymorphisms that inﬂuence histamine
receptor expression and/or activity remain to be determined.
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